{"id":3953,"date":"2024-10-16T12:24:14","date_gmt":"2024-10-16T12:24:14","guid":{"rendered":"https:\/\/www.english-culture.com\/?p=3953"},"modified":"2025-01-06T15:57:26","modified_gmt":"2025-01-06T15:57:26","slug":"nvax-waiting-for-better-times","status":"publish","type":"post","link":"https:\/\/www.english-culture.com\/nvax-waiting-for-better-times\/","title":{"rendered":"Nvax, waiting for better times"},"content":{"rendered":"
\"Novavax<\/a>
Novavax NVAX creating tomorrow vaccines today<\/figcaption><\/figure>\n

Nvax (Nasdaq)<\/a>. \u00abCreating tomorrow’s vaccines today\u00bb. Novavax Inc (Yahoo finance)<\/a> is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.<\/span><\/p>\n

In April 2017 I published an article about Novavax, from that date I bought and sold the stocks of the company several times, but without success. Then in 2020 at the start of the Covid pandemic it raised from 5$ to 290$ at the beginning of 2021, but unfortunately since I had others problems I didn’t buy it.<\/span><\/p>\n

In the meantime the company has changed a lot, and on May 10, 2024 Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines.<\/span><\/p>\n

This is the new profile of the company.<\/span><\/p>\n

We are a biotechnology company, with more than 1,545 employees, committed to helping to address serious infectious diseases globally through the discovery, development and delivery of innovative vaccines to patients around the world. We never rest in our quest to protect the health of people everywhere.<\/span><\/p>\n

Novavax is here to make a difference. We\u2019re a biotech company focused on developing life-saving vaccines to fight infectious diseases. We use solid science tested by decades of research to develop vaccines. We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies and foundations.<\/span><\/p>\n

The power & speed of nanoparticle technology<\/span><\/p>\n

Our vaccine technology combines power and speed with the immunogenicity-enhancing properties of our Matrix-M\u2122 adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases.<\/span><\/p>\n

Our people & culture<\/span><\/p>\n

Our team is experienced, compassionate, and focused on the future of vaccine development. While growing rapidly, we maintain that small company culture.<\/span><\/p>\n

Our Partners<\/span><\/p>\n

We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies and foundations.<\/span><\/p>\n

\"Novavax
Novavax NVAX Historical chart<\/figcaption><\/figure>\n

Novavax in Europe<\/span><\/p>\n

Novavax AB<\/span>
\nNovavax AB is headquartered in Uppsala, Sweden. This site is responsible for the research, development and manufacturing of our saponin adjuvants. Our Matrix-MTM is used in several vaccine candidates to enhance the immune response and stimulate high levels of neutralizing antibodies.<\/span><\/p>\n

Novavax CZ<\/span>
\nIn 2020, Novavax CZ was established, located in Bohumil, Czech Republic. This facility is an advanced biologics and vaccine manufacturing campus dedicated to the production of vaccines to protect global health.<\/span><\/p>\n

Novavax EU<\/span>
\nSince 2022, Novavax has started to develop its commercial hubs across Europe with its main regional headquarters in Zurich, Switzerland. Additional locations have been established in Brussels, Belgium and Barcelona, Spain.<\/span><\/p>\n

Our Headquarters:<\/span>
\nNovavax CH GmbH<\/span>
\nFraum\u00fcnsterstrasse 16<\/span>
\n8001 Z\u00fcrich<\/span>
\nSwitzerland<\/span><\/p>\n

<\/p>\n

\n
\n

<\/p>\n

\n
Track all markets on TradingView<\/span><\/a><\/div>\n